1 404

Cited 0 times in

Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer

DC FieldValueLanguage
dc.contributor.author손주혁-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.date.accessioned2015-07-15T16:58:14Z-
dc.date.available2015-07-15T16:58:14Z-
dc.date.issued2003-
dc.identifier.issn0277-3732-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/113964-
dc.description.abstractWe evaluated the efficacy and tolerability of a combination chemotherapy including infusional fluorouracil (5-FU), etoposide, and cisplatin (FEP) in 89 patients with advanced/relapsed gastric cancer. Primary endpoints were progression-free and overall survival. Secondary endpoints were response rates, response duration, and toxicity. The treatment schedule was as follows: 5-FU 1,000 mg/m2 and etoposide 100 mg/m2 were administered on 3 consecutive days and cisplatin at 80 mg/m2 was administered on day 2, and repeated every 3 weeks. The median times to progression and overall survival were 4 and 8 months, respectively. One-year progression-free and overall survival rates were 10% and 33%, respectively. The overall response rate for 25 eligible patients with measurable disease was 20% (5/25, complete response 2, partial response 3) with median response duration of 7 months. Median actual dose intensities of 5-FU, etoposide, and cisplatin were 700 mg/m2/wk, 70 mg/m2/wk, and 21 mg/m2/wk, respectively. Median relative dose intensities of 5-FU, etoposide, and cisplatin were 0.70, 0.70, and 0.63, respectively. In conclusion, the FEP regimen was found to produce therapeutic results similar to those of other combination chemotherapeutic studies and to have an acceptable toxicity. This regimen could be used as one of the options for advanced gastric cancer chemotherapy in patients unsuitable for doxorubicin-based regimens.-
dc.description.statementOfResponsibilityopen-
dc.format.extent203~209-
dc.relation.isPartOfAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHEtoposide/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy*-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHStomach Neoplasms/surgery-
dc.subject.MESHSurvival Analysis-
dc.titleInfusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer-
dc.typeArticle-
dc.contributor.collegeResearcher Institutes (부설 연구소)-
dc.contributor.departmentCancer Metastasis Research Center (암전이연구센터)-
dc.contributor.googleauthorJoo H. Sohn-
dc.contributor.googleauthorHei C. Jeung-
dc.contributor.googleauthorHyun C. Chung-
dc.contributor.googleauthorWoo I. Jang-
dc.contributor.googleauthorByung S. Kim-
dc.contributor.googleauthorJin S. Min-
dc.contributor.googleauthorSung H. Noh-
dc.contributor.googleauthorJae K. Roh-
dc.contributor.googleauthorSun Y. Rha-
dc.contributor.googleauthorHyun J. Shin-
dc.identifier.doi10.1097/01.COC.0000017800.63585.37-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01995-
dc.contributor.localIdA03773-
dc.contributor.localIdA01281-
dc.contributor.localIdA01316-
dc.contributor.localIdA03794-
dc.relation.journalcodeJ00075-
dc.identifier.eissn1537-453X-
dc.identifier.pmid12714898-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-200304000-00022&LSLINK=80&D=ovft-
dc.subject.keyword5-FU-
dc.subject.keywordEtoposide-
dc.subject.keywordCisplatin-
dc.subject.keywordGastric cancer-
dc.subject.keywordAdvanced-
dc.subject.keywordRelapsed-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.rights.accessRightsnot free-
dc.citation.volume26-
dc.citation.number2-
dc.citation.startPage203-
dc.citation.endPage209-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.26(2) : 203-209, 2003-
Appears in Collections:
5. Research Institutes (연구소) > Cancer Metastasis Research Center (암전이연구센터) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.